Reminder: New Oregon licensure requirements for pharma sales reps now in effect!

As we recently summarized online here, Oregon has approved a temporary rule implementing SB 763, which requires licensure of pharmaceutical sales representatives who visit health care providers in the state of Oregon for 15 or more days in a calendar year. Pharmaceutical manufacturers with sales representatives who visit customers in Oregon for 15 or more days per year should take steps to make sure their sales representatives apply for and obtain licensure.

Oregon’s temporary rule took effect January 1, and the state’s Department of Consumer and Business Services (DCBS) is also debating a proposed permanent rule that will govern long-term implementation of SB 763, to take effect in June 2022. SB 763 is similar to laws currently in effect in Chicago, Washington D.C., and Nevada, and incorporates some of the more onerous requirements from those other jurisdictions, including that licensees are required to complete continuing education and submit annual reports describing their contact with health care providers in Oregon. Oregon has already started to accept licensure applications in accordance with SB 763 via the National Insurance Producer Registry.

 

See our full analysis online here for more information, including a summary of who must obtain a license, the requirements to obtain and maintain licensure, and penalties under SB 763.

 

We will continue to monitor the revision and finalization of the rules implementing Oregon SB 763, and keep you apprised of any changes.

 

Authored by Ron Wisor and Laura Hunter

 

This website is operated by Hogan Lovells Solutions Limited, whose registered office is at 21 Holborn Viaduct, London, United Kingdom, EC1A 2DY. Hogan Lovells Solutions Limited is a wholly-owned subsidiary of Hogan Lovells International LLP but is not itself a law firm. For further details of Hogan Lovells Solutions Limited and the international legal practice that comprises Hogan Lovells International LLP, Hogan Lovells US LLP and their affiliated businesses ("Hogan Lovells"), please see our Legal Notices page. © 2022 Hogan Lovells.

Attorney advertising. Prior results do not guarantee a similar outcome.